Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI company today announces that, together with its U.S. based strategic partner Phesi Inc. (“Phesi”), the two companies have entered a joint commercial clinical development collaboration in an undisclosed disease area with a leading pharmaceutical company that is an existing client of Phesi.
The collaboration marks the first time that Sensyne and Phesi have entered a joint commercial collaboration with a pharmaceutical client since they entered into a strategic alliance in January 2021. The development work to be undertaken involves the analysis of anonymized and de-identified real-world patient data available to Sensyne with Phesi’s clinical trial data in order to optimize the design of a clinical trial program for the client.
No financial terms have been disclosed for this collaboration.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.